On Aug. 27, 2020, Pfizer and Shanghai Fosun Pharmaceutical announced an intended collaboration to supply 10 million doses of their BNT162 mRNA-based vaccine candidate against SARS-CoV-2, subject to clinical success and regulatory approval, to Hong Kong (Special Administrative Region of China, SAR) and Macao (SAR).

Fosun Industrial Co., Limited, a wholly owned subsidiary of Fosun Pharma has entered into the Letter of Intent with Jacobson Pharma in relation to the contemplated distribution of 10 million doses of vaccine targeting COVID-19 in Hong Kong SAR and Macao SAR on August 27, 2020.

BioNTech is one of the leading mRNA-based biopharmaceutical companies in the world. The Company will supply the vaccines from its GMP-certified mRNA manufacturing facilities in Europe. BioNTech and Fosun Pharma announced their strategic collaboration on March 13, 2020. The two companies are working jointly on the development and commercialization of potential COVID-19 vaccine products based on BioNTech’s mRNA technology platform in Mainland China, Hong Kong and Macau Special Administration Region and the Taiwan Region. The vaccine candidate is a prophylactic biological product, aiming to prevent COVID-19 in adults. A Phase 1 trial has already been initiated in China and the treatment of the first participants with one of the vaccine candidates from the BNT162 program, BNT162b1, was announced on August 5, 2020. 144 participants have already been fully enrolled in the Phase 1 study.